TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02003482

Intervention type: RADIATION
Intervention: Postop IMRT for head/neck cancer
Description: Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.

Intervention type: RADIATION
Intervention: Postop IMRT for head/neck cancer
Description: Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.

Intervention type: DEVICE
Intervention: CT for Radiation Treatment Planning
Description: Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment

Intervention type: DEVICE
Intervention: CT for Radiation Treatment Planning
Description: Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
Study: NCT03965845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.
Study: NCT02712177

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine
Study: NCT03965845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaglenestat (CB-839)
Description: Teleglenastat is an oral tablet administered twice daily with food at the assigned dose level. Dose is taken with palbociclib each day in 28-day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib Oral Capsule or Tablet [Ibrance]
Description: Palbociclib (Ibrance) is an oral capsule or tablet administered once daily with food on Days 1-21 of every 28-day cycle in combination with telaglenestat. Days 22-28 of every cycle, palbociclib is not taken.
Study: NCT02107534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent training (dyslexia)
Description: The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
Study: NCT03950232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod 2 mg tablet by mouth, once daily up to approximately 8 years or until marketing authorization is obtained in the participant's country, whichever comes first
Study: NCT02150239

Intervention type: PROCEDURE
Intervention: operation
Study: NCT04076475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: neuromuscular electrical stimulation
Description: Participants will receive muscular electrical stimulation on quadriceps muscle and abdominal muscles for 30 min/day for 10 days
Study: NCT01387932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HepaSphere/QuadraSphere Microspheres
Description: HepaSphere/QuadraSphere Microspheres loaded with doxorubicin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVA, lipiodol, doxorubicin
Description: Conventional TACE procedure using PVA, lipiodol and doxorubicin
Study: NCT01443871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy
Description: Subject will assigned inhale aromatherapy
Study: NCT02242487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVT-301
Study: NCT03112135

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Topical TXA 1 gm diluted in 200 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenalin
Description: Topical adrenaline 1 mg diluted on 200 ml saline
Study: NCT02233595

Intervention type: RADIATION
Intervention: Chemoradiation
Study: NCT04370314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dental prosthetics
Description: Implant-supported crowns
Study: NCT04218890

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
Description: urinary sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
Description: urinary sample

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary tissue factor (TF), tissue factor pathway inhibitor (TFPI) and plasmin
Description: urinary sample
Study: NCT01902147

Intervention type: OTHER
Intervention: Postoperative Quality Recovery Scale (PQRS)
Description: The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
Study: NCT04961021

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strabismus surgery
Description: Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Strabismus surgery
Description: Strengthening of medial rectus muscle or strengthening of medial rectus muscle with weakening of the lateral rectus muscle
Study: NCT03111160

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SMILE procedure using lower energy (100, 105, and 110 nJ)
Description: Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SMILE procedure using conventional energy (115 to 150 nJ)
Description: The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
Study: NCT02712177

Intervention type: BIOLOGICAL
Intervention: conjugated pneumococcal vaccine

Intervention type: BIOLOGICAL
Intervention: MMRV

Intervention type: BIOLOGICAL
Intervention: MMRV
Study: NCT03825263

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Pressure Compression
Description: The intervention group use the IPC device for 6 months. Clinic assessment were completed at the beginning and at 3 and 6 months. Participants in the intervention group were invited to use the IPC device twice a day every day during this period.
Study: NCT01112423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 2 mg, once daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 10 mg, once daily, 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-823778
Description: Capsules, Oral, 20 mg, once daily, 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, Oral, 0 mg, once daily, 28 days
Study: NCT02142257

Intervention type: PROCEDURE
Intervention: Gastric Bypass
Description: Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.

Intervention type: DEVICE
Intervention: AspireAssist Aspiration Therapy
Description: AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
Study: NCT04015440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HBMT
Description: Individual is presented with words with some letters missing and told to complete the word.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Other Training
Description: Alternative to HBMT training
Study: NCT04542005

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: q3h albuterol
Description: Using q3h albuterol as discharge criteria from hospital
Study: NCT03447236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feuerstein Program
Description: Mediated learning cognitive enhancement program
Study: NCT04048668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: tDCS is a non-invasive brain stimulation technique by which very small electrical currents (2 mA) are applied to the scalp.
Study: NCT02379715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desflurane
Study: NCT01338987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: Leuprolide: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients \<18 years) between day -13 and day -20 pre-bone marrow transplant but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients \> 18 years and as a 3 month injection (adult preparation) for patients \< 18 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F FLT
Description: For the first 23 patients undergoing 1st bone marrow transplant (BMT):\[18F\]fluorothymidine (18F FLT): 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days) For 2nd BMT: 18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day -1, + 28, day 60 and at relapse (+/- 5 days)
Study: NCT03709901

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Allograft
Description: Injection of viable allograft into the nucleus pulposus of the degenerated disc

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of sterile normal saline (0.9% sodium chloride) into the nucleus pulposus of the degenerated disc
Study: NCT03361488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trained anesthesiogist
Study: NCT01459809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE
Description: Pharmaceutical form: oral~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLIMEPIRIDE
Description: Pharmaceutical form: oral~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: Pharmaceutical form: oral~Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: METFORMIN
Description: Pharmaceutical form: oral~Route of administration: oral
Study: NCT03789292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P17 SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P17 SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Humira SC
Description: Subcutaneous injection of Adalimumab 40mg every two weeks
Study: NCT02343302

Intervention type: DEVICE
Group type: OTHER
Intervention: Jackson-Pratt Drain
Description: A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain

Intervention type: DEVICE
Group type: OTHER
Intervention: Jackson-Pratt Drain
Description: A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-suctioning drainage
Description: A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain

Intervention type: DEVICE
Group type: OTHER
Intervention: Non-suctioning drainage
Description: A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain
Study: NCT03596671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RENOVA iStim™ System
Description: Tibial implantable neuromodulation device
Study: NCT00508482

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: deep needling
Description: Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.~Once a day, five times a week, four weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose
Description: 20-30ml, once a day before breakfast, for the whole study except the run-in period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: shallow needling
Description: Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
Study: NCT03652714

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ganglion sphenopalatine block with local anesthetic
Description: Block performed with bilaterally inserted q-tips with 1:1 mixture of lidocaine 40mg/ml and ropivacaine 5mg/mL.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Ganglion sphenopalatine block with placebo
Description: Block performed with bilaterally inserted q-tips with isotone NaCl
Study: NCT00308334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: 10 mg po TID X 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo- Sugar pill
Description: placebo po TID x 14 days
Study: NCT02536664

Intervention type: DRUG
Intervention: Rituximab

Intervention type: DRUG
Intervention: Rituximab
Study: NCT03736629

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: 8 weeks of Azithromycin (250 mg) once daily by mouth
Study: NCT02771899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spineEOS software
Description: During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: spineEOS software
Description: During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on spineEOS software will be performed.
Study: NCT01338987

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide: 60 mg/kg intravenous (IV) on days -4 and -3 (for Adults \> 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric \</= 22 years)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate:10 mg/m(2) intravenous (IV) on day +1, and 5 mg/m(2) IV Days + 3, 6, 11
Study: NCT02771899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
Study: NCT01443871

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Pure water
Description: Subject will assigned inhale Pure water
Study: NCT00714441

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle and Activities Education Program (LEAP-AHEAD)
Description: Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
Study: NCT02771899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EOS
Description: The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.